Results
Five trials studying 4 different doses of magnesium sulfate reported on the primary outcome of poor 3-to 6-month neurologic function (defined as death or dependency according to a modified Rankin Scale score of 4 to 5 or death, or a Glasgow Outcome Scale score of 1 to 3) and the secondary outcome of delayed cerebral ischemia (defined at least 3 different ways by the individual investigators). Outcome results were determined overall and for 5 predetermined time categories reflecting the interval from aneurysmal subarachnoid hemorrhage to treatment onset. Quality of evidence was reported for only 1 of the 5 included trials. 1 There was no significant difference in the adjusted risk of death, disability, or delayed cerebral ischemia between the magnesium and control groups in patients who
Comparison of magnesium versus placebo for primary and secondary outcomes based on individual patient-level meta-analysis from 5 trials. 
STUDY SELECTION
The authors included randomized trials comparing magnesium sulfate with placebo for the treatment of aneurysmal subarachnoid hemorrhage.
DATA EXTRACTION AND SYNTHESIS
Two authors independently abstracted data, which were analyzed at the individual patient level. Quality of evidence was determined according to masking, outcome, analysis type, and loss to follow-up. Risk ratios for the primary outcome of death or dependency at 3 to 6 months and the secondary outcome of delayed cerebral ischemia were calculated.
were treated within 6, between 6 and 12, or between 12 and 24 hours after aneurysmal subarachnoid hemorrhage. The low number of patients treated within 6 hours resulted in a wide and therefore imprecise confidence interval around this point estimate.
Commentary
In the United States, 21,000 to 33,000 people each year are affected by subarachnoid hemorrhage, with 80% of cases occurring as a result of intracranial aneurysm rupture. 2 Subarachnoid hemorrhage can have devastating consequences, including almost 50% mortality and significant neurologic sequelae in survivors, with poor outcomes attributed to delayed cerebral ischemia, a frequent complication of aneurysmal subarachnoid hemorrhage. 3 It is generally believed that delayed cerebral ischemia occurs as a result of vasospasm, which can theoretically be reversed by early administration of magnesium, a calcium antagonist. Although trials to date evaluating the utility of magnesium as a neuroprotective agent for aneurysmal subarachnoid hemorrhage have had negative results, they are limited by small sample sizes, which have precluded time-interval analyses focused on administration of magnesium within the initial 24 hours. 4 To address the obstacle of insufficient power, the review authors performed an individual patient data meta-analysis of existing trials and found no beneficial effect of early magnesium for the treatment of aneurysmal subarachnoid hemorrhage.
Patients enrolled in the included trials were generally representative of the emergency department (ED) population, but the dosage and method of magnesium administration varied from study to study, which was uncontrolled for in the results. The clinical and radiographic definitions of delayed cerebral ischemia were similarly heterogeneous, and the primary outcomes were limited to functional scales, with no consideration of cognitive, psychological, or quality-of-life indicators. The authors were unable to assess methodological quality for 4 of the 5 trials, and their results relied heavily on data from their own MASH (magnesium for aneurysmal subarachnoid hemorrhage)-2 study, which contributed greater than 60% of the patients analyzed, but radiologic severity of aneurysmal subarachnoid hemorrhage, which is an independent predictor of outcomes, was not included in the adjusted analysis. 5 Although the authors planned their subgroup analysis a priori, the number of patients in each of the intervals was small, and there was no reported sample size calculation to support definitively rejecting early benefit of magnesium therapy according to their results.
In accordance with this systematic review with several limitations, there is no evidence to support the routine administration of intravenous magnesium sulfate for the treatment of aneurysmal subarachnoid hemorrhage, yet larger and more rigorous studies are required before any potential benefit of early administration in the ED setting can be definitively excluded. 
